Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$20.22
-HK$0.68(-3.17%)
At close: 4:00 PM EDT
HK$20.22
-HK$0.68(-3.17%)
Day’s Range― - ―
52-Week RangeHK$18.76 - HK$35.34
Previous CloseN/A
Volume2.14M
Average Volume (3M)5.91M
Market Cap
HK$21.60B
Enterprise ValueHK$24.84K
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Sep 02, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$38.70Price Target Upside91.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.15B
Bulls Say, Bears Say
Bulls Say
Revenue Growth AccelerationA sustained >60% revenue increase in 2025 indicates meaningful commercial traction and faster adoption of the robotics platform. Over 2–6 months this growth supports a larger installed base, which should translate into more recurring consumables and service revenue, improving long-term unit economics as utilization rises.
Recurring Consumables & Services ModelThe business model mixes upfront system sales with recurring instrument and service revenue, giving revenue visibility as installed base grows. This structural mix supports durable margin expansion potential and cash conversion improvements once procedure volumes increase, reducing dependence on one-time system sales.
Improving LeverageMeaningful deleveraging cut financial stress and interest burden, improving solvency and optionality for capital allocation. Over the medium term this moderation of leverage lowers refinancing risk and gives management more flexibility to invest in commercialization and R&D while losses persist.
Bears Say
Persistent Net LossesA roughly -45% net margin shows the company is still far from operating profitability. Continued losses erode equity and require external funding to sustain growth initiatives. Over months this limits free reinvestment, risks dilution, and makes the path to sustainable profit and self-funded growth uncertain.
Negative Operating Cash FlowRepeated negative operating and free cash flow means the company remains reliant on financing to cover operations and capex. Even with improvement versus prior year, persistent cash burn and volatile FCF hinder the ability to scale manufacturing, expand sales channels, and achieve consistent margin recovery without external capital.
Very Weak Return On EquityA -59% ROE signals capital is being consumed rather than generating returns. Over time this undermines shareholder value and makes raising new equity or debt on favorable terms harder, constraining strategic options and potentially increasing the cost of capital during the critical commercialization phase.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$18.76 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$21.60B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 25 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.162 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.162.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is 0.03.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.162 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.136%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$38.70
▲(91.37% Upside)
Technical Analysis
MicroPort Scientific
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―